HPS Pharmacies wish to advise that Pfizer Australia Pty Ltd, in consultation with the Therapeutic Goods Administration (TGA) have given notice of a drug recall for product correction of:
Xalkori® (crizotinib) Capsules
|Expiry Date||31 May 2016||31 August 2016|
This recall has been issued due to the identification of foreign particles in some blister packs of Xalkori® (crizotinib) 200mg and 250mg capsules in Europe.
Pfizer advises these foreign particles are not dangerous and their presence is considered to pose a negligible risk to patient safety. The particles discovered were small, thin, soft, and metallic, and were found to adhere to the blister foil rather than the capsule when removing a capsule from the blister pocket.
Healthcare professionals are requested to advise patients to wash capsules immediately prior to use.
Pfizer have NOT requested that stock be discarded or returned. New supplies of unaffected stock are expected to be available from the end of March 2015.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies, or Pfizer Medical Information on 1800 675 229.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.